Clinical trial · Observational
Non Invasive Detection of Lung and Breast Cancer by Odor Signature
A Clinical Study Design to Evaluate the Specificity and Sensitivity of Our Novel System for Detection of Breast and Lung Cancer by Odor Signature
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators have developed an early detection solution for lung and breast cancer. A system which can distinguish between different medical odors based on biosensors. Our product is user-friendly noninvasive, nonradioactive and nontoxic to the patients. The technology enables a high level of sensitivity and provides users with a quick lab response and a simple yes or no answer. The aim of this study is to contribute and detect the patient at the earliest possible stage, in a noninvasive, nonradioactive and nontoxic way. Exhaled breath and urine samples are a promising approach towards future possible lung and breast cancer screening method.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| non-invasive detection of cancer odor | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Breast Cancer patients
- interventionNames
- Other: non-invasive detection of cancer odor
- label
- Lung cancer patients
- interventionNames
- Other: non-invasive detection of cancer odor
- label
- Healthy controls
- interventionNames
- Other: non-invasive detection of cancer odor
Primary outcomes (1)
- measure
- The sensitivity and specificity of our biosensors in lung and breast cancer detection
- timeFrame
- 3 years
- description
- We will measure the ability of our biosensors to detect lung and breast cancer in urine samples from patients. Each urine sample will be subjected to 5 biosensors. If 3 out of 5 will report positively, the sample will be marked as cancerous. Each type of cancer (lung or breast) will be detected by different groups of biosensors, trained specifically to detect the specific cancer type. After the data of the detections will be collected, statistical analysis will be calculated in order to evaluate the sensitivity and specificity of our biosensor in cancer detection.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosed Lung Cancer patients * Diagnosed Breast Cancer patients Exclusion Criteria: * Cancer patients who were treated using chemotherapy * Cancer patients who were treated using radiation * Cancer patients who were treated using biological treatments * Cancer patients who were treated with chemotherapy * Cancer patients who were treated with any anti- cancer therapies * Cancer patients who use drugs that affect the immune system
References
Publications (0)
Data not yet available